Nascent Biotech, Inc. (OTCQB: NBIO)

Nascent Biotech Inc. (OTCQB: NBIO)


Company Summary

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biopharmaceutical company focused on cancer research, particularly with respect to cancers that affect the brain. NBIO develops human antibodies and cytokine responses for the treatment of various forms of cancer and the antibodies have strong antiviral applications as well. While brain cancers were always the core research focus, its monoclonal antibodies are intended to treat malignancies, such as glioblastoma and malignant astrocytoma, lung and breast cancer metastases to the brain, pancreatic cancer, and as importantly, viruses like COVID-19.

Key Metrics @ 7/20/2020

Closing Price $0.0935
52 Week Range $0.052 to $0.35
Shares Outstanding 63.672M
Shares in the Float 26.69M
% Held by Insiders 33.92%
Common Shares Authorized 500M
Average Daily Volume: 10 Day 148,250
Market Cap $6.112M
Reporting Status SEC Reporting
Financials Audited
Most Recent Filing: 10-K  for 03/31/20 Filed:  06/22/2020
Fiscal Year-end 03/31

(Source: OTC Markets, Yahoo Finance, SEC filings)

Corporate News and Market Drivers

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) — Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “The laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.” 

SAN DIEGO, CA / ACCESSWIRE / June 3, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) (the “Company” or “Nascent”) is pleased to provide a corporate update and summary with a recent interview the Company’s CEO, Sean Carrick, presented on SNN Network. The complete interview may be seen on the SNN Network at

San Diego, CA, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Nascent Biotech, Inc. (OTCQB: NBIO), an emerging biotech company, with IND Clearance and IRB approval to begin Clinical trials for Brain Cancer, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.

The updated report provides an overview of recent events, new initiatives, and the Company’s valuation relative to its peer group.  The sponsored research update also carries a rating and a price target and can be accessed and requested by email at [email protected]

Marble Arch Research notes that, “With a number of competitive advantages in the space, Nascent’s Primary Asset, Pritumumab, has several additional promising indications, a strong IP portfolio, and with beginning Phase I clinical studies, we believe that Nascent Biotech can enjoy hockey-stick type growth in the stock price within the next 3-6 months.”  

Bottom Line Observation

In a coverage initiation report issued by Marble Arch Research, Inc., Robert Sassoon, Senior Analyst on January 14, 2020, the analyst rated NBIO as a Speculative Buy with a Price Target Range of $0.38 to $0.76

To get a copy of the report, email [email protected]

NBIO has seen an upward movement from $0.10/share on 01/02/2020 to a 52-week high of $0.35 on 3/30/2020… approaching the lower range of Marble Arch’s price target…only to work its way back down to today’s close at $0.0932.

I’d suggest that if you like what you read about NBIO, this looks like a pretty good entry point to start accumulating shares.

I haven’t been following NBIO as closely as some other microcaps, but they certainly appear to have a committed senior management team; evidenced by the fact that the CEO, CFO and Executive VP just converted over $1.1 million of company liability to them into common stock.  

And, the guys closest to the Company ought to know what they’re talking about…here’s some comments worth considering:

Nascent Executive Vice President of Business Development Brandon Price stated, “My strong belief in the Company, and the clinical value of our Pritumumab treatment for brain cancer, compel me to further take a position in its future and help advance our asset.”

Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value.  The IND clearance by the FDA, along with the pending clinical trials, gives me confidence in its growth.”

Nascent CEO Sean Carrick added, “The confidence in the Company by the management team, with their dedication and financial support, should positively impact our shareholders and the market as we continue our effort to monetize Nascent’s assets.”

By Mike Casson,

Executive Editor and Senior Analyst


About Nascent Biotech, Inc.:

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an IND application before the FDA required for Clinical trials.  Its products are not commercially available. For further information please visit our website


Sean Carrick
President | CEO
Nascent Biotech, Inc.
330 Nancy Ridge Dr
Suite 105
San Diego CA 92121
772.713.0541 Cell
[email protected]

Disclaimer and Disclosures: Green Leaf Investing, Green Leaf or GLI is a financial publisher and not a FINRA broker/dealer or investment adviser. Green Leaf is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. GLI did not receive any compensation for this article. However, officers, employees and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. GLI and/or affiliates may from time to time receive cash and/or equity compensation from featured companies for corporate communications services. In the interest of full disclosure, Mike Casson, GLI’s Executive Editor is also president of Casson Communications, LLC (CCLLC) and Founder/Executive Editor of MicroCap MarketPlace, affiliated companies. Even though no compensation has been received by any of the affiliated companies, you should be aware of these potential conflicts of interest. We believe the information contained herein and in our publications to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.


Research and Editorial Staff

© 2020 Green Leaf Investing, All Rights Reserved